OctoPlus Announces Delisting of Shares

Leiden, the Netherlands, 15 March 2013 - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces that, following the acquisition of 98.6% of all issued and outstanding ordinary shares in the Company (the "Shares") by Reddy Netherlands B.V., a fully-owned subsidiary of Dr. Reddy's Laboratories Ltd., delisting of the Shares was approved by NYSE Euronext Amsterdam. The delisting of the Shares will take effect on 16 April 2013. The last trading day will be 15 April 2013. The Company is reminding shareholders that following delisting shareholders will no longer be able to trade the Shares via the NYSE Euronext Amsterdam stock exchange in the usual way. Furthermore, it remains uncertain if, to what extent, under which conditions and at what cost processing of the Shares in the Euroclear giro system may be continued after delisting. This is a press release by OctoPlus N.V. pursuant to the provision of Article 5:25i of the Dutch Act on the Financial Supervision (Wet op het financieel toezicht). About OctoPlus OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult to formulate active pharmaceutical ingredients. OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl. In addition, OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics. This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version. Click here for the press release in PDF: http://hugin.info/137076/R/1685731/552396.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: OctoPlus N.V. via Thomson Reuters ONE [HUG#1685731]